Self-modulating therapeutic platform using engineered miRNA-responsive oligonucleotides

Due to a pivotal role in the post-transcriptional regulation of genes implicated in numerous diseases, miRNAs serve as promising disease biomarkers and therapeutic targets. We introduce a new oligonucleotide probe termed miRNA-trigger, which selectively downregulates newly assigned target mRNAs by hijacking specific miRNAs. By engineering the miRNA-trigger to suppress the anti-apoptotic BCL-xL gene, we induce apoptosis selectively in breast cancer cells overexpressing specific miRNAs and further validate its therapeutic efficacy in vivo, by significantly reducing the tumor volume of the xenograft mouse upon its tail-vein injection. This approach establishes a new platform for self-modulating oligonucleotide therapy by redirecting disease-associated miRNAs.

Authors

Institutions

Publication Details

Journal
Nano Convergence
Published
2025-06-30
DOI
https://doi.org/10.1186/s40580-025-00499-w
Citations
1
Primary Topic
Advanced biosensing and bioanalysis techniques
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Self-modulating therapeutic platform using engineered miRNA-responsive oligonucleotides

Namseok Lee, Junhyeok Yoon, JinA Lim, Kyunghoon Hur et al.
1 citations
Nano Convergence
Advanced biosensing and bioanalysis techniques
0.81
article

Self-modulating therapeutic platform using engineered miRNA-responsive oligonucleotides

Namseok Lee, Junhyeok Yoon, JinA Lim, Kyunghoon Hur, Ryeongeun Cho, Doyeong Ku, Jong‐Eun Park, Hyun Gyu Park, Yoosik Kim, Luke P. Lee, Junshik Hong, Jayeon Song, Hansol Kim, Sun‐Joon Min, Jun Liu
article en
1 citations

Abstract

Due to a pivotal role in the post-transcriptional regulation of genes implicated in numerous diseases, miRNAs serve as promising disease biomarkers and therapeutic targets. We introduce a new oligonucleotide probe termed miRNA-trigger, which selectively downregulates newly assigned target mRNAs by hijacking specific miRNAs. By engineering the miRNA-trigger to suppress the anti-apoptotic BCL-xL gene, we induce apoptosis selectively in breast cancer cells overexpressing specific miRNAs and further validate its therapeutic efficacy in vivo, by significantly reducing the tumor volume of the xenograft mouse upon its tail-vein injection. This approach establishes a new platform for self-modulating oligonucleotide therapy by redirecting disease-associated miRNAs.

Nano ConvergenceVol. 12(1)
Brigham and Women's Hospital (US), Harvard University (US), Seoul National University (KR), Korea Advanced Institute of Science and Technology (KR), Sungkyunkwan University (KR), University of California, Berkeley (US)
National Research Foundation, National Research Foundation of Korea, Ministry of Science and ICT, South Korea, Samsung
Good health and well-being
Openalex Percentile: Top 26%
Advanced biosensing and bioanalysis techniques
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.